Iranian Researchers Produce, Develop Dialysis Water Treatment Systems

Dialysis is a life-saving treatment method for patients who cannot perform kidney functions due to serious kidney diseases like kidney failure. This treatment is used to clean and balance harmful waste and excess fluid in the patient's blood. Dialysis plays a vital role in enabling patients to continue their lives; however, the quality of the water used in this treatment process profoundly affects the patient's health and the efficacy of the treatment. Calculations for "fluid balance" are commonly made to determine the daily fluid intake of dialysis patients.

Patients with kidney failure require dialysis treatment to clean the accumulated harmful waste from their bodies and to substitute for urine production. This process involves filtering the patient’s blood through a dialysis machine. However, this cleaning process can only be effectively done with high-quality, purified water. Clean water is used to carry toxins and excess fluid that needs to be removed from the patient's body. If the water is not adequately clean, the accumulation of harmful waste can worsen the patient’s health.

The quality and flow of ultra-pure water are continuously monitored during the hemodialysis session. In case of any issues, the system automatically triggers an alarm and notifies healthcare professionals for necessary intervention.

“One of the member companies of this consortium produces 16 types of dialysis machine filters, and another company has produced four types of dialysis machine products, including sets, solutions, powders, and needles,” said Behnam Hoshiaripour, the marketing manager of the Iranian knowledge-based companies and a member of Iranian Consortium of Dialysis.

Hoshiaripour pointed to the production of dialysis machine, RO machine as other achievements of the member companies of the consortium, adding, “One of the companies is in charge of setting up dialysis departments in medical centers, education, publishing and printing affairs, has put on agenda along with another company the production of peritoneal dialysis machine serum and solution.”

The commercial manager of the knowledge-based company further referred to the membership of one of the pharmaceutical companies in the consortium, adding, “This company is focused on the production of rare drugs for kidney diseases and intends to produce this kind of drugs.”

As regards the production of the dialysis machine in their company, Hoshiaripour said, “In addition to having an operation license, this machine has also succeeded in obtaining the European CE standard and it is currently utilized in the dialysis departments of medical centers.”

He pointed to the Hemodiafiltration (HDF) as one of the latest achievements of their company, and added that the Hemodiafiltration is a new treatment compared to hemodialysis.

He furthur said that in the hemodialysis machine, water is placed next to the machine, but in this machine, we sterilize a volume of water and inject it into the patient's blood; therefore, in this method, unlike the hemodialysis machine, the quality and sterilization of the water is very important.

“The hemodiafiltration device needs a dialysis water purification device which is also produced by the technicians in this company. We are the only manufacturer of this device in the country.”

“This device is useful for patients in terms of removing middle molecules, because in the hemodialysis machine, only small molecule substances are separated from the patient's blood, which after a while, due to the accumulation of middle molecular toxins in the blood, ground will be laid for appearance of diseases in the people with kidney diseases,” the company’s marketing manager said.

He considered 25% of the complications caused by dialysis to be related to decline in blood pressure, stressing, “Blood pressure drop has been reduced in hemodiafiltration treatment.”

According to him, the device has successfully passed the tests, expressing hope that it will enter the commercialization phase in the next six months.

4155/i